296 related articles for article (PubMed ID: 32289279)
21. The advent of AAV9 expands applications for brain and spinal cord gene delivery.
Dayton RD; Wang DB; Klein RL
Expert Opin Biol Ther; 2012 Jun; 12(6):757-66. PubMed ID: 22519910
[TBL] [Abstract][Full Text] [Related]
22. Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy.
Gong Y; Berenson A; Laheji F; Gao G; Wang D; Ng C; Volak A; Kok R; Kreouzis V; Dijkstra IM; Kemp S; Maguire CA; Eichler F
Hum Gene Ther; 2019 May; 30(5):544-555. PubMed ID: 30358470
[TBL] [Abstract][Full Text] [Related]
23. Transduction Profile of the Marmoset Central Nervous System Using Adeno-Associated Virus Serotype 9 Vectors.
Matsuzaki Y; Konno A; Mukai R; Honda F; Hirato M; Yoshimoto Y; Hirai H
Mol Neurobiol; 2017 Apr; 54(3):1745-1758. PubMed ID: 26884266
[TBL] [Abstract][Full Text] [Related]
24. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease.
Bucher T; Colle MA; Wakeling E; Dubreil L; Fyfe J; Briot-Nivard D; Maquigneau M; Raoul S; Cherel Y; Astord S; Duque S; Marais T; Voit T; Moullier P; Barkats M; Joussemet B
Hum Gene Ther; 2013 Jul; 24(7):670-82. PubMed ID: 23799774
[TBL] [Abstract][Full Text] [Related]
25. Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury.
Hirai T; Enomoto M; Kaburagi H; Sotome S; Yoshida-Tanaka K; Ukegawa M; Kuwahara H; Yamamoto M; Tajiri M; Miyata H; Hirai Y; Tominaga M; Shinomiya K; Mizusawa H; Okawa A; Yokota T
Mol Ther; 2014 Feb; 22(2):409-419. PubMed ID: 24322332
[TBL] [Abstract][Full Text] [Related]
26. Intrathecal shRNA-AAV9 inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice.
Hirai T; Enomoto M; Machida A; Yamamoto M; Kuwahara H; Tajiri M; Hirai Y; Sotome S; Mizusawa H; Shinomiya K; Okawa A; Yokota T
Hum Gene Ther Methods; 2012 Apr; 23(2):119-27. PubMed ID: 22583159
[TBL] [Abstract][Full Text] [Related]
27. Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration.
Hinderer C; Katz N; Dyer C; Goode T; Johansson J; Bell P; Richman L; Buza E; Wilson JM
Mol Ther Methods Clin Dev; 2020 Jun; 17():969-974. PubMed ID: 32420410
[TBL] [Abstract][Full Text] [Related]
28. Intrathecal Delivery of AAV Vectors in Cynomolgus Macaques for CNS Gene Therapy and Gene Expression Analysis in Microdissected Motor Neurons.
Borel F; Adams E; Mueller C
Methods Mol Biol; 2019; 1937():295-303. PubMed ID: 30706405
[TBL] [Abstract][Full Text] [Related]
29. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.
Benkhelifa-Ziyyat S; Besse A; Roda M; Duque S; Astord S; Carcenac R; Marais T; Barkats M
Mol Ther; 2013 Feb; 21(2):282-90. PubMed ID: 23295949
[TBL] [Abstract][Full Text] [Related]
30. Subpial Adeno-associated Virus 9 (AAV9) Vector Delivery in Adult Mice.
Tadokoro T; Miyanohara A; Navarro M; Kamizato K; Juhas S; Juhasova J; Marsala S; Platoshyn O; Curtis E; Gabel B; Ciacci J; Lukacova N; Bimbova K; Marsala M
J Vis Exp; 2017 Jul; (125):. PubMed ID: 28745630
[TBL] [Abstract][Full Text] [Related]
31. Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion.
Castle MJ; Cheng Y; Asokan A; Tuszynski MH
Sci Adv; 2018 Nov; 4(11):eaau9859. PubMed ID: 30443600
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery.
Kagiava A; Richter J; Tryfonos C; Leal-Julià M; Sargiannidou I; Christodoulou C; Bosch A; Kleopa KA
Sci Rep; 2021 Dec; 11(1):23358. PubMed ID: 34857831
[TBL] [Abstract][Full Text] [Related]
33. More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose-response and comparison to AAV PHP.B.
Dayton RD; Grames MS; Klein RL
Gene Ther; 2018 Aug; 25(5):392-400. PubMed ID: 30013186
[TBL] [Abstract][Full Text] [Related]
34. Intraneural convection enhanced delivery of AAVrh20 for targeting primary sensory neurons.
Pleticha J; Jeng-Singh C; Rezek R; Zaibak M; Beutler AS
Mol Cell Neurosci; 2014 May; 60():72-80. PubMed ID: 24769104
[TBL] [Abstract][Full Text] [Related]
35. Intrathecal sc-AAV9-CB-GFP: Systemic Distribution Predominates Following Single-Dose Administration in Cynomolgus Macaques.
Meseck EK; Guibinga G; Wang S; McElroy C; Hudry E; Mansfield K
Toxicol Pathol; 2022 Jun; 50(4):415-431. PubMed ID: 35658751
[TBL] [Abstract][Full Text] [Related]
36. AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice.
Besse A; Astord S; Marais T; Roda M; Giroux B; Lejeune FX; Relaix F; Smeriglio P; Barkats M; Biferi MG
Mol Ther; 2020 Aug; 28(8):1887-1901. PubMed ID: 32470325
[TBL] [Abstract][Full Text] [Related]
37. Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice.
Iida A; Takino N; Miyauchi H; Shimazaki K; Muramatsu S
Biomed Res Int; 2013; 2013():974819. PubMed ID: 23762870
[TBL] [Abstract][Full Text] [Related]
38. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.
Samaranch L; Salegio EA; San Sebastian W; Kells AP; Foust KD; Bringas JR; Lamarre C; Forsayeth J; Kaspar BK; Bankiewicz KS
Hum Gene Ther; 2012 Apr; 23(4):382-9. PubMed ID: 22201473
[TBL] [Abstract][Full Text] [Related]
39. Improved gene delivery to adult mouse spinal cord through the use of engineered hybrid adeno-associated viral serotypes.
Siu JJ; Queen NJ; Huang W; Yin FQ; Liu X; Wang C; McTigue DM; Cao L
Gene Ther; 2017 Jun; 24(6):361-369. PubMed ID: 28440798
[TBL] [Abstract][Full Text] [Related]
40. Targeting the somatosensory system with AAV9 and AAV2retro viral vectors.
Skorput AGJ; Gore R; Schorn R; Riedl MS; Marron Fernandez de Velasco E; Hadlich B; Kitto KF; Fairbanks CA; Vulchanova L
PLoS One; 2022; 17(3):e0264938. PubMed ID: 35271639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
